title: [Safety and epidemiological effects of the first China-made mass A (H1N1) influenza vaccination].
abstract: OBJECTIVE
  To evaluate the safety and epidemiological effects on the first mass vaccination program, using the China-made A (H1N1) influenza vaccine.
  
  
  METHODS
  Descriptive epidemiology and cohort study design were used to assess the influenza A H1N1 vaccine on its safety and epidemiological effects.
  
  
  RESULTS
  95 244 subjects were immunized with A (H1N1) influenza vaccine. 193 adverse events were reported through AEFI Management System, with the Reported rates of AEFI as 2.03‰. Most of the adverse events (137/193, 71.0%) happened during the first 24 hours after immunization was carried out. Of 81 adverse reactions confirmed to be related to immunization, with 78 (96.3%) showed mild reactions. No Guillain-Barre Syndrome related to vaccination was reported through the AEFI Management System. The epidemiological protection rate of A (H1N1) vaccine could reach 80.9% when the coverage was not considered.
  
  
  CONCLUSIONS
  The A (H1N1) influenza vaccine showed a similar safety profile to seasonal flu vaccine. The vaccine demonstrated a good epidemiological effects against A (H1N1) influenza virus infection.
authors.affiliation: Beijing Center for Disease Control and Prevention, Beijing 100013, China.
authors.forename: Wen-yan
authors.initials: WY
authors.lastname: Ji
authors.forename: Li
authors.initials: L
authors.lastname: Lu
authors.forename: Min
authors.initials: M
authors.lastname: Lü
authors.forename: Liang
authors.initials: L
authors.lastname: Miao
authors.forename: Ting
authors.initials: T
authors.lastname: Gao
authors.forename: Ruo-gang
authors.initials: RG
authors.lastname: Huang
authors.forename: Luo-dan
authors.initials: LD
authors.lastname: Suo
authors.forename: Dong-lei
authors.initials: DL
authors.lastname: Liu
authors.forename: Rui
authors.initials: R
authors.lastname: Ma
authors.forename: Rui
authors.initials: R
authors.lastname: Yu
authors.forename: Jia-zi
authors.initials: JZ
authors.lastname: Zhangzhu
authors.forename: Wei-xiang
authors.initials: WX
authors.lastname: Liu
authors.forename: Yang
authors.initials: Y
authors.lastname: Zeng
authors.forename: Xiao-mei
authors.initials: XM
authors.lastname: Li
authors.forename: Jiang
authors.initials: J
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002681:China; D015331:Cohort Studies; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000276:immunology; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D032541:Mass Vaccination; D008875:Middle Aged; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines